Laurel Wealth Advisors, Inc. Bluebird Bio, Inc. Transaction History

Laurel Wealth Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $120,687 - $147,782	-6,690 Closed	0 $0
Q4 2020 Mar 03, 2021	SELL	$27.5 - $37.92 $93,197 - $128,510	-3,389 Reduced 33.62%	6,690 $289,000
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $347,120 - $440,956	10,079 New	10,079 $544,000
Q3 2019 Nov 13, 2019	SELL	$59.47 - $93.1 $119,534 - $187,131	-2,010 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$75.84 - $105.21 $1,516 - $2,104	-20 Reduced 0.99%	2,010 $256,000
Q1 2019 May 16, 2019	SELL	$64.44 - $104.11 $14,112 - $22,800	-219 Reduced 9.74%	2,030 $319,000
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $58,154 - $91,767	-984 Reduced 30.44%	2,249 $144,000
Q3 2018 Nov 15, 2018	BUY	$88.86 - $117.49 $84,417 - $111,615	950 Added 41.61%	3,233 $471,000
Q2 2018 Aug 20, 2018	BUY	$99.64 - $127.59 $101,832 - $130,396	1,022 Added 81.05%	2,283 $357,000
Q1 2018 May 16, 2018	BUY	$105.8 - $150.94 $133,413 - $190,335	1,261 New	1,261 $215,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Laurel Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Laurel Wealth Advisors, Inc. with notifications on news.